Photodynamic agents with anti-metastatic activities

Area of Science:

• Materials Science
• Biomedical Engineering
• Oncology

Background:

• Photodynamic therapy (PDT) is a promising cancer treatment modality.
• Developing multifunctional anticancer agents with both direct tumor-killing and anti-metastatic properties is a key challenge.
• Zinc phthalocyanine derivatives have shown potential as photosensitizers for PDT.

Purpose of the Study:

• To investigate the potential of Tetrakis-(diisopropyl-guanidino) zinc phthalocyanine (Zn-DIGP) as a multifunctional anticancer agent.
• To evaluate Zn-DIGP's efficacy as a photodynamic therapy agent and its anti-metastatic activities in vivo.
• To elucidate the mechanism of Zn-DIGP's anti-metastatic action.

Main Methods:

• Synthesis and characterization of Zn-DIGP.
• Assessment of cellular uptake and dark toxicity in vitro.
• Evaluation of phototoxicity upon red laser light (660 nm) irradiation.
• In vivo studies using C57BL/6 mice with B16F10 melanoma cells to assess anti-metastatic activity.
• Investigation of Zn-DIGP's effect on chemokine CXCL10 and G protein-coupled receptor CXCR3 signaling.

Main Results:

• Zn-DIGP demonstrated good cellular uptake and low dark toxicity (EC50 > 80 μM).
• High singlet oxygen quantum yield (Φ ≈ 0.51) resulted in potent phototoxicity (EC50 ≈ 0.16 μM).
• Zn-DIGP significantly inhibited lung colony formation in vivo, indicating anti-metastatic potential.
• Zn-DIGP competitively inhibited CXCR3 activation (IC50 = 3.8 μM), interfering with CXCL10 signaling and causing receptor degradation.
• Zn-DIGP induced CXCL10 overexpression, suggesting a feedback regulatory mechanism.

Conclusions:

• Zn-DIGP is a potent multifunctional anticancer agent combining PDT with light-independent anti-metastatic activity.
• The anti-metastatic effect is mediated by interference with the CXCL10/CXCR3 signaling pathway.
• Zn-DIGP represents a novel therapeutic strategy for treating primary tumors and preventing metastasis.